The slide above depicts the failure of GlaxoSmithKline (GSK_) and Prosensa’s (RNA_) drisapersen to improve the walking ability of boys with Duchenne muscular dystrophy. The companies announced the disappointing results from the drisapersen trial on Sept. 20 but detailed data were presented Saturday at the World Muscle Society meeting. What you’re looking at in the slide above is pretty much the worst-case scenario for drisapersen. Sarepta Therapeutics (SRPT_) no longer has to be concerned with competition from Glaxo and Prosensa, regardless of whether FDA approves eteplirsen quickly or asks for a pre-approval phase III study.
Help employers find you! Check out all the jobs and post your resume.
